Free shipping on all orders over $ 500

WYC-209

Cat. No. M10507
WYC-209 Structure
Synonym:

WYC209

Size Price Availability Quantity
5mg USD 390  USD390 In stock
10mg USD 640  USD640 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

WYC-209 is a novel inhibitor of tumor-repopulating cells (trcs), inducing trc apoptosis primarily via the caspase 3 pathway. WYC-209 induces apoptosis primarily via the caspase 3 pathway with IC50 of 0.19 μM for inmalignant murine melanoma TRCs.

In vivo, WYC-209 (0.022-0.22 mg/kg; i.v.; once every two days for 25 days) inhibits tumor metastasis in C57BL/6 mice bearing lung metastases.

Protocol (for reference only)
Cell Experiment
Cell lines A2780, A549, MCF-7, MDA-MB-435s, A375 cells
Preparation method Human ovarian cancer A2780 (a), human lung cancer A549 (b), human breast cancer MCF-7 (c), human melanoma MDA-MB-435s (d), and human malignant melanoma A375 (e) were cultured in 90-Pa fibrin gels for 3 days and treated with 0.1, 1, or 10 μM WYC-209. f–j A2780, A549, MCF-7, MDA-MB-435s, and A375 were cultured in 90-Pa fibrin gels for 3 days, treated with 10 μM WYC-209, and were then washed out of the compound on day 4.
Concentrations 10 μM
Incubation time 24 hours
Animal Experiment
Animal models Female immune-competent C57BL/6 mice
Formulation 0.1% DMSO
Dosages 0.022, 0.22 mg/kg
Administration intravenously injected; once every two days for 25 days
Chemical Information
Molecular Weight 368.45
Formula C20H20N2O3S
CAS Number 2131803-90-0
Solubility (25°C) DMSO 70 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Junwei Chen, et al. Nat Commun. Inhibition of cancer stem cell like cells by a synthetic retinoid

Related RAR/RXR Products
MSU-42011

MSU-42011 is an orally active retinoid X receptor-like (RXR) agonist that potently inhibits the expression of iNOS as well as p-ERK protein levels. In addition, MSU-42011 has immunomodulatory and antitumor activities for cancer research.

KCL-286

KCL-286 is an orally active retinoic acid receptor-beta (RAR-beta) agonist for studies related to spinal cord injury.

XS-060

XS-060 is a potent anticancer agent and RXRα antagonist.

BPA-B9

BPA-B9 is a RXRα ligand and antagonist targeting the pRXRα-PLK1 interaction.

ER 50891 quarterhydrate

ER 50891 quarterhydrate is a potent antagonist of retinoic acid receptor α(RARα).

  Catalog
Abmole Inhibitor Catalog




Keywords: WYC-209, WYC209 supplier, RAR/RXR, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.